Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

References

• Ulin M, Ali M, Chaudhry ZT, et al. Uterine fibroids in menopause and perimenopause. Menopause. 2020;27(2):238–242.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Longo DL. Uterine fibroids. N Engl J Med. 2013;369(14):1344–1355.
   PubMed Web of Science ®Google Scholar
• Stewart EA, Solomon CG. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646–1655.
   PubMed Web of Science ®Google Scholar
• Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211e1–9.
   Web of Science ®Google Scholar
• Yang Q, Diamond MP, Al-Hendy A. Converting of myometrial stem cells to tumor-initiating cells: mechanism of uterine fibroid development. Cell Stem Cells Regen Med. 2016;2(1):1-3..
   Google Scholar
• Clarke-Pearson DL, Geller EJ. Complications of hysterectomy. Obstet Gynecol. 2013;121(3):654–673.
   PubMed Web of Science ®Google Scholar
• Lonnee-Hoffmann R, Pinas I. Effects of Hysterectomy on Sexual Function. Curr Sex Health Rep. 2014;6(4):244–251.
   PubMedGoogle Scholar
• Cook H, Ezzati M, Segars JH, et al. The impact of uterine leiomyomas on reproductive outcomes. Minerva Ginecol. 2010;62(3):225–236.
   PubMedGoogle Scholar
• Owen C, Armstrong AY. Clinical management of leiomyoma. Obstet Gynecol Clin North Am. 2015;42(1):67–85.
   PubMed Web of Science ®Google Scholar
• Ali M, Chaudhry ZT, Al-Hendy A. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018;13(2):169–177.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;2:CD000547. 10.1002/14651858.CD000547
   PubMedGoogle Scholar
• Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109(10):1097–1108.
   PubMed Web of Science ®Google Scholar
• Sabry M, Al-Hendy A. Medical treatment of uterine leiomyoma. Reprod Sci. 2012;19(4):339–353.
   PubMed Web of Science ®Google Scholar
• Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: understanding advantages and limitations. J Hum Reprod Sci. 2014;7(3):170–174.
   PubMedGoogle Scholar
• Conn PM, Ulloa-Aguirre A. Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol. 2011;62:109–141.
   PubMedGoogle Scholar
• Ali M, Al-Hendy A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod. 2017;97(3):337–352.
   PubMed Web of Science ®Google Scholar
• Donnez J, Arriagada P, Marciniak M, et al. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17(12):1225–1232.
   PubMed Web of Science ®Google Scholar
• Meunier L, Meszaros M, Pageaux G-P, et al. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol. 2020;44(3):e45–e49.
   PubMed Web of Science ®Google Scholar
• EMA, Ulipristal acetate for uterine fibroids: EMA recommends restricting use. https://www.ema.europa.eu/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products, 2020: p. Accessed Feb 2021.
   Google Scholar
• Lamb YN. Elagolix: first Global Approval. Drugs. 2018;78(14):1501–1508.
   PubMed Web of Science ®Google Scholar
• Schwartz K, Llarena NC, Rehmer JM, et al. The role of pharmacotherapy in the treatment of endometriosis across the lifespan. Expert Opin Pharmacother. 2020;21(8):893–903.
   PubMed Web of Science ®Google Scholar
• Chen C, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4 -methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–7485.
   PubMed Web of Science ®Google Scholar
• Ng J, Chwalisz K, Carter DC, et al. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–1691. .
   PubMed Web of Science ®Google Scholar
• Shebley M, Polepally AR, Nader A, et al., Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 59(3): 297–309. 2020. .
   PubMed Web of Science ®Google Scholar
• Winzenborg I, Nader A, Polepally AR, et al. Population pharmacokinetics of elagolix in healthy women and women with endometriosis. Clin Pharmacokinet. 2018;57(10):1295–1306. .
   PubMed Web of Science ®Google Scholar
• Orilissa™. [United States package insert]. North Chicago, IL: AbbVie Inc; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210450s000lbl.pdf Accessed Feb 2021..
   Google Scholar
• Ng J, Duan WR, Marbury T, et al. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment. Clin Pharmacol Drug Dev. 2019;8(8):1053–1061.
   PubMed Web of Science ®Google Scholar
• Archer DF, et al. Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women. J Clin Endocrinol Metab. 2020;105(3).
   Web of Science ®Google Scholar
• Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–551.
   PubMed Web of Science ®Google Scholar
• Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108(1):152–160.
   PubMed Web of Science ®Google Scholar
• Carr BR, Stewart EA, Archer DF, et al. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: a Randomized Controlled Trial. Obstet Gynecol. 2018;132(5):1252–1264.
   PubMed Web of Science ®Google Scholar
• Winzenborg I, Polepally AR, Nader A, et al. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: an Application of Markov Model. CPT Pharmacometrics Syst Pharmacol. 2020;9(8):466–475. .
   PubMedGoogle Scholar
• Review EM, US FDA Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf, 2018. Accessed Jan 2021.
   Google Scholar
• Chiney MS, Ng J, Gibbs JP, et al. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2020;59(5):617–627.
   PubMed Web of Science ®Google Scholar
• Polepally AR, Ng JW, Salem AH, et al. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. J Clin Pharmacol. 2020;60(12):1606–1616.
   PubMed Web of Science ®Google Scholar
• Nader A, et al. Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy. Clin Pharmacokinet. 2020.
   Web of Science ®Google Scholar
• Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019;9(5):497–515.
   PubMed Web of Science ®Google Scholar
• Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21(3):363–371. .
   PubMed Web of Science ®Google Scholar
• Carr B, Giudice L, Dmowski WP, et al. Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: a Randomized Controlled Study. J Endometr Pelvic Pain Disord. 2013;5(3):105–115.
   Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al., Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 377(1): 28–40. 2017.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Soliman AM, Agarwal SK, et al. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril. 2019;112(2):298–304. e3.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Soliman AM, Pokrzywinski RM, et al. Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: a Pooled Analysis of Two Phase III Trials of Elagolix. J Sex Med. 2020;17(12):2427–2433.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019;34(2):193–199.
   PubMed Web of Science ®Google Scholar
• Archer DF, et al. Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Ther Adv Reprod Health 2020;14:2633494120964517.
   Google Scholar
• Taylor HS. Use of elagolix in gynaecology. J Obstet Gynaecol Can. 2018;40(7):931–934.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019;55(4):237–246.
   PubMed Web of Science ®Google Scholar
• Ford B. Elagolix (Orilissa) for Endometriosis Pain. Am Fam Physician. 2019;100(8):502–504.
   PubMed Web of Science ®Google Scholar
• Melis GB, Neri M, Corda V, et al. Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxicol. 2016;12(5):581–588.
   PubMed Web of Science ®Google Scholar
• Leyland N, Estes SJ, Lessey BA, et al. A clinician’s guide to the treatment of endometriosis with elagolix. J Womens Health (Larchmt). 2020. 10.1089/jwh.2019.8096.
   PubMed Web of Science ®Google Scholar
• Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015;11(1):19–28.
   PubMedGoogle Scholar
• Bradley CA. Reproductive endocrinology: elagolix in endometriosis. Nat Rev Endocrinol. 2017;13(8):439.
   PubMedGoogle Scholar
• Poulos C, et al. Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020. p. 1–9.
   PubMed Web of Science ®Google Scholar
• Dun EC, Taylor HS. Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain. Oncotarget. 2017;8(59):99219–99220.
   PubMedGoogle Scholar
• Taylor HS, Soliman AM, Johns B, et al. Health-related quality of life improvements in patients with endometriosis treated with elagolix. Obstet Gynecol. 2020;136(3):501–509.
   PubMed Web of Science ®Google Scholar
• Alessandro P, Luigi N, Felice S, et al. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature. Arch Gynecol Obstet. 2017;295(4):827–832.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Soliman AM, Johns B, et al. Real-world characterization of women with diagnosed endometriosis initiating therapy with elagolix using a US claims database. Clinicoecon Outcomes Res. 2020;12:473–479.
   PubMed Web of Science ®Google Scholar
• Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019;19(4):343–360.
   PubMed Web of Science ®Google Scholar
• Pokrzywinski R, Soliman AM, Surrey E, et al. Psychometric assessment of the PROMIS Fatigue Short Form 6a in women with moderate-to-severe endometriosis-associated pain. J Patient Rep Outcomes. 2020;4(1):86.
   PubMedGoogle Scholar
• Pokrzywinski RM, Soliman AM, Snabes MC, et al. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertil Steril. 2021;115(2):423–430.
   PubMedGoogle Scholar
• Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018;27(5):445–458.
   PubMed Web of Science ®Google Scholar
• Winzenborg I, Soliman AM, Shebley M. A personalized medicine approach using clinical utility index and exposure-response modeling informed by patient preferences data. CPT Pharmacometrics Syst Pharmacol. 2021;10(1):40–47.
   PubMedGoogle Scholar
• Pokrzywinski R, et al. responsiveness evaluation and recommendation for responder thresholds for endometriosis health profile-30: analysis of two phase iii clinical trials. J Womens Health (Larchmt). 2020;29(2):253–261.
   PubMed Web of Science ®Google Scholar
• Pokrzywinski RM, et al. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. Am J Obstet Gynecol. 2020;222(6):592 e1–592 e10.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, et al. Endometriosis-related pain reduction during bleeding and nonbleeding days in women treated with elagolix. J Pain Res. 2021;14:263–271.
   PubMed Web of Science ®Google Scholar
• Pokrzywinski RM, et al. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials. Fertil Steril. 2019;112(3):545–551.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Soliman AM, Palac HL, et al. Impact of elagolix on workplace and household productivity among women with moderate to severe pain associated with endometriosis: a pooled analysis of two phase III trials. Patient. 2019;12(6):651–660.
   PubMedGoogle Scholar
• Schlaff WD, et al., Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 382(4): 328–340. 2020.
   PubMed Web of Science ®Google Scholar
• Simon JA, et al. Elagolix treatment for up to 12 Months in women with heavy menstrual bleeding and uterine Leiomyomas. Obstet Gynecol. 2020;135(6):1313–1326.
   PubMed Web of Science ®Google Scholar
• Slomski A. Elagolix reduces fibroid-related heavy menstrual bleeding long-term. JAMA. 2020;324(8):733.
   Web of Science ®Google Scholar
• Neri M, et al., Clinical utility of elagolix as an oral treatment for women with uterine fibroids: a short report on the emerging efficacy data. Int J Womens Health, 2019. 11:535–546.
   PubMed Web of Science ®Google Scholar
• Angioni S, D’Alterio MN, Daniilidis A. Highlights on medical treatment of uterine fibroids. Curr Pharm Des. 2021;26. 10.2174/1381612826666210101152820.
   Google Scholar
• Farris M, Bastianelli C, Rosato E, et al. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157–178.
   PubMed Web of Science ®Google Scholar
• Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis. Expert Opin Pharmacother. 2017;18(13):1391–1397.
   PubMed Web of Science ®Google Scholar
• Review EM, US FDA Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf., 2018. Accessed Feb 2021.
   Google Scholar
• ORIAHNN™. ORIAHNN™ (elagolix) [United States package insert]. North Chicago, IL: AbbVie Inc; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213388s000lbl.pdf
   Google Scholar
• Abbas Suleiman A, et al. Exposure-safety analyses identify predictors of change in bone mineral density and support elagolix labeling for endometriosis-associated pain. CPT Pharmacometrics Syst Pharmacol. 2020;9(11):639–648.
   PubMedGoogle Scholar
• Surrey E, et al. Long-Term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–160.
   PubMed Web of Science ®Google Scholar
• Kilpatrick RD, Chiuve SE, Leslie WD, et al. Estimating the effect of elagolix treatment for endometriosis on postmenopausal bone outcomes: a model bridging Phase III Trials to an older real-world population. JBMR Plus. 2020;4(12):e10401.
   PubMedGoogle Scholar
• Al-Hendy A, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2021;224(1):72 e1–72 e50. .
   PubMed Web of Science ®Google Scholar
• Wang ST, et al. Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. J Comp Eff Res. 2019;8(5):337–355.
   PubMed Web of Science ®Google Scholar
• Kashani BN, et al. Role of medical management for uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2016;34:85–103.
   PubMed Web of Science ®Google Scholar
• Wagenfeld A, Saunders PTK, Whitaker L, et al. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045–1054.
   PubMed Web of Science ®Google Scholar
• Singh SS, Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments. Curr Med Res Opin. 2015;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• Mercorio F, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67(4):277–280.
   PubMed Web of Science ®Google Scholar
• Machado RB, et al. The levonorgestrel-releasing intrauterine system: its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids. Gynecol Endocrinol. 2013;29(5):492–495.
   PubMed Web of Science ®Google Scholar
• Maruo T, Ohara N, Matsuo H, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007;75(6):S99–103.
   PubMed Web of Science ®Google Scholar
• Song H, et al. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;10:CD009505.
   PubMed Web of Science ®Google Scholar
• Doherty L, Mutlu L, Sinclair D, et al. Uterine fibroids: clinical manifestations and contemporary management. Reprod Sci. 2014;21(9):1067–1092.
   PubMed Web of Science ®Google Scholar
• Segars JH, et al. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum Reprod Update. [2014];20(3):309–333.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol. 2002;99(5 Pt 1):709–719.
   PubMed Web of Science ®Google Scholar
• Moroni RM, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015;3:CD010854.
   PubMed Web of Science ®Google Scholar
• Lusher SJ, Raaijmakers HCA, Vu-Pham D, et al. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators. J Biol Chem. 2011;286(40):35079–35086.
   PubMed Web of Science ®Google Scholar
• Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol. 2014;30(10):683–684.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175–1189.
   PubMed Web of Science ®Google Scholar
• Donnez J, Arriagada P, Donnez O, et al. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr Opin Obstet Gynecol. 2015;27(6):422–431.
   PubMed Web of Science ®Google Scholar
• Schutt B, Kaiser A, Schultze-Mosgau M-H, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016;31(8):1703–1712.
   PubMed Web of Science ®Google Scholar
• Ciebiera M, Vitale SG, Ferrero S, et al. Vilaprisan, a New selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough? Curr Pharm Des. 2020;26(3):300–309.
   PubMed Web of Science ®Google Scholar
• Murji A, Whitaker L, Chow TL, et al. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;4:CD010770.
   PubMed Web of Science ®Google Scholar
• (EMA), E.M.A., Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. https://www.ema.europa.eu/en/news/suspension-ulipristal-acetate-uterine-fibroids-during-ongoing-ema-review-liver-injury-risk, 2020. Accessed Jan 2021.
   Google Scholar
• Fantasia HC. Elagolix as a novel treatment for endometriosis-related pain. Nurs Womens Health. 2019;23(4):366–369.
   PubMedGoogle Scholar
• Barra F, Vitale SG, Seca M, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas. Expert Opin Pharmacother. 2020;21(12):1419–1430.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral Gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133(3):423–433.
   PubMed Web of Science ®Google Scholar
• Kavoussi SK, Esqueda AS, Jukes LM. Elagolix to medically treat a uterine adenomyoma: a case report. Eur J Obstet Gynecol Reprod Biol. 2020;247:266–267.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019;112(5):922–929. e2.
   PubMed Web of Science ®Google Scholar
• Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–2196.
   PubMed Web of Science ®Google Scholar
• Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019;55(8):503–512.
   PubMed Web of Science ®Google Scholar